TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31414586

Group type: COMPARATOR
Intervention: Metabolically unhealthy obese (MUO) group
Number of subjects: 301

Group type: COMPARATOR
Intervention: Metabolically healthy obese (MHO) group
Number of subjects: 301
Study: 29318917

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (20-minute session) combined with manual therapy (15-minute session) and therapeutic exercise (15-minute session)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Inspiratory muscle training (20-minute session)
Number of subjects: 43
Study: 27390979

Group type: EXPERIMENTAL
Intervention: Trimetazidine (35 mg tablet/twice daily for 4 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no trimetazidine)
Number of subjects: 40
Study: 24974847

Group type: EXPERIMENTAL
Intervention: TANC1 locus
Number of subjects: 741
Study: 22124605

Group type: EXPERIMENTAL
Intervention: Resistance-type exercise (75% one repetition maximum)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Endurance-type exercise (50% maximum workload capacity)
Number of subjects: 45
Study: 19579590

Group type: EXPERIMENTAL
Intervention: Preoperative serum levels of TPA (cut off level = 53 IU/L) after liver resection
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Preoperative serum levels of TPS (cut off level = 81 IU/L) after liver resection
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Preoperative serum levels of TPA after RFA
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Preoperative serum levels of TPS after RFA
Number of subjects: 173
Study: 17505265

Group type: EXPERIMENTAL
Intervention: Interferon alpha2b 10 million units/m(2) subcutaneously three times a week plus rh-Endostatin 45 mg/m(2) subcutaneously every 12 h (arm A)
Number of subjects: 21

Group type: COMPARATOR
Intervention: rh-Endostatin alone (arm B)
Number of subjects: 21
Study: 15370023

Group type: EXPERIMENTAL
Intervention: Buprenorphine treatment in a specialist clinic
Number of subjects: 115

Group type: COMPARATOR
Intervention: Buprenorphine treatment in a shared care setting
Number of subjects: 115
Study: 11462292

Group type: EXPERIMENTAL
Intervention: SonoVue (0.3, 0.6, 1.2, and 2.4 mL intravenous bolus injection)
Number of subjects: 40
Study: 9740292

Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate at a dose of 20 mg/kg/day for 20 days (group A)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate at a dose of 20 mg/kg/day for 30 days (group B)
Number of subjects: 54
Study: 8058855

Group type: EXPERIMENTAL
Intervention: TV news program designed to expose myths about NGRI
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Brief factual report about NGRI
Number of subjects: 50

Group type: COMPARATOR
Intervention: Neutral program
Number of subjects: 50
Study: 2972756

Group type: EXPERIMENTAL
Intervention: 5 mg diazepam
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (painful stimulation)
Number of subjects: 10
Study: 28712467

Group type: EXPERIMENTAL
Intervention: Antisocial in-group paired with prosocial out-group
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Antisocial in-group paired with antisocial out-group
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (younger children)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Resource allocation behavior
Number of subjects: 2
Study: 27044854

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 70 mg/kg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 8
Study: 25006914

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 23986157

Group type: EXPERIMENTAL
Intervention: 20% alpha-hydroxy/polyhydroxy acid emollient
Number of subjects: 25

Group type: COMPARATOR
Intervention: 6% salicylic acid cream
Number of subjects: 25
Study: 20349368

Group type: EXPERIMENTAL
Intervention: Visibly-descriptive names
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Psychologically-descriptive names
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Non-descriptive names
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Visibly-descriptive names for older adults
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Psychologically-descriptive names for older adults
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Non-descriptive names for older adults
Number of subjects: 52
Study: 18754533

Group type: EXPERIMENTAL
Intervention: Low power laser (LPL) therapy (9‐11 joules/cm2) over the carpal tunnel area
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham laser therapy
Number of subjects: 80
Study: 15948202

Group type: EXPERIMENTAL
Intervention: Linear-EIM in patients with radiculopathy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Linear-EIM in normal subjects
Number of subjects: 20
Study: 12911781

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT) with Alutard(R)‐SQ, Dermatophagoides pteronyssinus extract, administered with increasing doses until maintenance dose reached, then once a month for 12 months.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo preparation, identical to the active preparation.
Number of subjects: 36
Study: 10575594

Group type: EXPERIMENTAL
Intervention: 600 mg ipriflavone orally daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: 20 units elcatonin, weekly injected intramuscularly
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Comparison of bone gainers with increase of lumbar spine BMD by 2% or more with bone losers with a decrease by 2% or more
Number of subjects: 30
Study: 8767354

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg effervescent tablet
Number of subjects: 24

Group type: COMPARATOR
Intervention: Al-Mg-hydroxide 10 ml
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 1901321

Group type: EXPERIMENTAL
Intervention: Fleroxacin (600 mg/d for 72 hours)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fleroxacin
Number of subjects: 18
Study: 7125177

Group type: EXPERIMENTAL
Intervention: 2 mg morphine base (2.63 mg morphine hydrochloride) in 10 ml 0.9% sodium chloride
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2 mg morphine base in 10 ml 5% glucose
Number of subjects: 60

Group type: COMPARATOR
Intervention: 10 ml 5% glucose as placebo
Number of subjects: 60
Study: 30651127

Group type: EXPERIMENTAL
Intervention: Biological mesh
Number of subjects: 496

Group type: COMPARATOR
Intervention: Synthetic mesh
Number of subjects: 496
Study: 27775992

Group type: EXPERIMENTAL
Intervention: rAd‐p53+CRT
Number of subjects: 162

Group type: COMPARATOR
Intervention: CRT
Number of subjects: 162

Group type: COMPARATOR
Intervention: rAd‐p53
Number of subjects: 162
Study: 25454363

Group type: EXPERIMENTAL
Intervention: 1-piece IOL (Tecnis ZCB00)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 3-piece IOL (Tecnis ZA9003)
Number of subjects: 50
Study: 23634982

Group type: EXPERIMENTAL
Intervention: ProActive Heart intervention (telephone-based health coaching)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 430
Study: 21494226

Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diet (LCD)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Low-Fat Diet (LFD)
Number of subjects: 270
Study: 19524752

Group type: EXPERIMENTAL
Intervention: Real interferential therapy (IFT), 12 sessions for 4 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo interferential therapy (IFT), 12 sessions for 4 weeks
Number of subjects: 33
Study: 16087140

Group type: EXPERIMENTAL
Intervention: Chronic beta-blockade with carvedilol or metoprolol
Number of subjects: 19
Study: 14616423

Group type: EXPERIMENTAL
Intervention: Sublingual cobalamin (500 micro g daily)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral cobalamin (500 micro g daily)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral vitamin B complex (two tablets daily)
Number of subjects: 30
Study: 10977385

Group type: EXPERIMENTAL
Intervention: Torasemide
Number of subjects: 193

Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 193
Study: 9038554

Group type: EXPERIMENTAL
Intervention: Continuous postoperative femoral nerve block with 0.5% bupivacaine (5 ml/h for 48 h) plus PCA with morphine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group using PCA device alone
Number of subjects: 20
Study: 1824621

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal laser angioplasty (PTLA) followed by balloon dilatation
Number of subjects: 167

Group type: COMPARATOR
Intervention: Long-term treatment with phenprocumarol
Number of subjects: 167

Group type: COMPARATOR
Intervention: Long-term treatment with acetylsalicylic acid (ASA) plus dipyridamole
Number of subjects: 167

Group type: COMPARATOR
Intervention: Patients younger than 60 years
Number of subjects: 167

Group type: COMPARATOR
Intervention: Patients with reduced peripheral runoff
Number of subjects: 167

Group type: COMPARATOR
Intervention: Recanalized segments shorter than 7 cm
Number of subjects: 167

Group type: COMPARATOR
Intervention: Recanalized segments longer than 7 cm
Number of subjects: 167
Study: 6362342

Group type: EXPERIMENTAL
Intervention: 100 mg atenolol
Number of subjects: 52

Group type: COMPARATOR
Intervention: 100 mg metoprolol
Number of subjects: 52
Study: 31521123

Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST)
Number of subjects: 1219
Study: 28964569

Group type: EXPERIMENTAL
Intervention: Natural diet plus soy-whey blended protein (BP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Natural diet only (ND)
Number of subjects: 24
Study: 26315978

Group type: EXPERIMENTAL
Intervention: Measurement-based care
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 120
Study: 24237035

Group type: EXPERIMENTAL
Intervention: 10 mg ATRA given 1 hour before and for 7 days following oral typhoid vaccine
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control interventions (various)
Number of subjects: 46
Study: 21968605

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Hydroxypropyl methylcellulose (HPMC)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Oil-in-water emulsion (Emustil unidose; SIFI)
Number of subjects: 75
Study: 19326065

Group type: EXPERIMENTAL
Intervention: Quadsparing (QS) approach
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard procedure (midvastus approach)
Number of subjects: 50
Study: 17329652

Group type: EXPERIMENTAL
Intervention: Lay health worker outreach plus media-based education
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Media-based education only
Number of subjects: 1005
Study: 15878731

Group type: EXPERIMENTAL
Intervention: HrSz group
Number of subjects: 0

Group type: COMPARATOR
Intervention: NC group
Number of subjects: 0
Study: 12504050

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (RT) after surgery
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: Preoperative RT
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: Definitive RT
Number of subjects: 1058

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: Postoperative RT after marginal resections
Number of subjects: 1058
Study: 10517767

Group type: EXPERIMENTAL
Intervention: Immunocal (20 g/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Casein placebo
Number of subjects: 20
Study: 8915874

Group type: EXPERIMENTAL
Intervention: Bivalent attenuated cold‐recombinant (CR) vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inactivated trivalent subvirion vaccine (TIV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natural influenza virus infection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2065463

Group type: EXPERIMENTAL
Intervention: 5 mg clopamide
Number of subjects: 17

Group type: COMPARATOR
Intervention: 25 mg hydrochlorothiazide
Number of subjects: 17
Study: 6344309

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Pindolol (2.5 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Terbutaline (0.5 mg subcutaneous) after propranolol and pindolol
Number of subjects: 11
Study: 31801746

Group type: EXPERIMENTAL
Intervention: Early intervention programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 27573420

Group type: EXPERIMENTAL
Intervention: Interactive, multimedia cervical cancer education program (one-time, low-literacy, delivered in English or Spanish)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 0
Study: 26908675

Group type: EXPERIMENTAL
Intervention: PARENT (Parent-focused Redesign for Encounters, Newborns to Toddlers)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Control (usual well-child care)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: PARENT
Number of subjects: 251
Study: 24793714

Group type: EXPERIMENTAL
Intervention: Teaching video with interactive simulation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham video
Number of subjects: 28
Study: 22515882

Group type: EXPERIMENTAL
Intervention: Periodontal attachment loss
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Gingival recession
Number of subjects: 45
Study: 20391953

Group type: EXPERIMENTAL
Intervention: Tilactase (15 minutes before control H2-LBT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri (b.i.d. during 10 days before control H2-LBT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (15 minutes before control H2-LBT)
Number of subjects: 60
Study: 17290057

Group type: EXPERIMENTAL
Intervention: Vinblastine (5 mg/m2/dose) and Methotrexate (30 mg/m2/dose), administered weekly for 26 weeks and every other week for an additional 26 weeks.
Number of subjects: 28
Study: 15811605

Group type: EXPERIMENTAL
Intervention: ACLD subjects
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 22
Study: 11684174

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Patients with idiopathic Parkinson's disease (PDs)
Number of subjects: 2
Study: 9628448

Group type: EXPERIMENTAL
Intervention: Combination of aspirin and heparin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel antithrombotic treatments (direct thrombin inhibitors, platelet fibrinogen receptor antagonists, low-molecular-weight heparins)
Number of subjects: 0
Study: 7611185

Group type: EXPERIMENTAL
Intervention: Gram-Sure
Number of subjects: 88

Group type: COMPARATOR
Intervention: Vancomycin susceptibility (5 micrograms and 30 micrograms)
Number of subjects: 88
Study: 2093746

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control
Number of subjects: 22
Study: 862493

Group type: EXPERIMENTAL
Intervention: Incision
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Marsupialization
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Excision without primary closure
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Returning to work before wound healed
Number of subjects: 96

Group type: COMPARATOR
Intervention: Resuming work a week after epithelization
Number of subjects: 96
Study: 30111291

Group type: EXPERIMENTAL
Intervention: Transdiagnostic occupational rehabilitation intervention based on Acceptance and Commitment Therapy (3½ weeks duration)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Benefit work assessment allowance
Number of subjects: 212

Group type: COMPARATOR
Intervention: Partial sick leave
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Poor economy at baseline
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Reduced emotional functioning at baseline
Number of subjects: 212
Study: 27030504

Group type: EXPERIMENTAL
Intervention: Autologous dental pulp stem cell therapy (up to 10 million cells)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Autologous dental pulp stem cell therapy (maximum tolerable dose)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Autologous dental pulp stem cell therapy combined with 9 weeks of intensive task-specific rehabilitation
Number of subjects: 27
Study: 25319228

Group type: EXPERIMENTAL
Intervention: Silexan (1 × 160 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 21996661

Group type: EXPERIMENTAL
Intervention: Group-based behavioral weight-loss program with frequent friend and family support
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Group-based behavioral weight-loss program with no family support
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Group-based behavioral weight-loss program with no friend support
Number of subjects: 267
Study: 19200613

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg/d for 4 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Ezetimibe 20 mg/d for 4 weeks
Number of subjects: 22
Study: 18680888

Group type: EXPERIMENTAL
Intervention: Personal death condition
Number of subjects: 98

Group type: COMPARATOR
Intervention: Typical death condition
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 98
Study: 16280943

Group type: EXPERIMENTAL
Intervention: CCLS intervention
Number of subjects: 149

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 149
Study: 12393680

Group type: EXPERIMENTAL
Intervention: Cyclosporine regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: No cyclosporine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 0
Study: 10579658

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8904937

Group type: EXPERIMENTAL
Intervention: Brief, low-intensity tobacco cessation interventions including counseling by allied professionals, videos, written materials, and telephone calls.
Number of subjects: 0
Study: 1791224

Group type: EXPERIMENTAL
Intervention: Peptide T (D‐ala1‐peptide T amide) infused at 10(‐7) mol/L
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 14
Study: 7055177

Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Clindamycin plus Gentamicin
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (no antibiotics)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Comparison to controls
Number of subjects: 75
Study: 31564512

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg once daily for 6 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Water without any drug (negative control)
Number of subjects: 28
Study: 29663407

Group type: EXPERIMENTAL
Intervention: Ground-beef containing 25% total fat (25F)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ground-beef containing 18% total fat (18F)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ground-beef containing 18% total fat (18F) and 25% total fat (25F)
Number of subjects: 12
Study: 27769609

Group type: EXPERIMENTAL
Intervention: High cardiorespiratory fitness (CRF) defined as VO2peak >27.5 mL/kg/min in women and >34.4 mL/kg/min in men
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Sedentary time
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Decrement in VO2peak (1 metabolic equivalent)
Number of subjects: 874
Study: 24856992

Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive pressure ventilation (NIPPV)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 100
Study: 22223479

Group type: EXPERIMENTAL
Intervention: Infliximab therapy
Number of subjects: 106

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 106
Study: 20828455

Group type: EXPERIMENTAL
Intervention: Natural drying without a topical regimen
Number of subjects: 150

Group type: COMPARATOR
Intervention: Cleansing with 95% alcohol after daily bathing
Number of subjects: 150
Study: 17845862

Group type: EXPERIMENTAL
Intervention: Subcutaneous carbon dioxide insufflations
Number of subjects: 126

Group type: COMPARATOR
Intervention: Sham ultrasound
Number of subjects: 126
Study: 16219121

Group type: EXPERIMENTAL
Intervention: Guided self-help intervention
Number of subjects: 114

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 114
Study: 14633142

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg/day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 36
Study: 10965615

Group type: EXPERIMENTAL
Intervention: Ulinastatin (600,000 units in priming solution, 300,000 units in bypass circuit, 300,000 units daily for 5 days post-surgery)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 0
Study: 9047091

Group type: EXPERIMENTAL
Intervention: Metformin (1.7 g daily for 4 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8418166

Group type: EXPERIMENTAL
Intervention: 50 micrograms of an RSV subunit vaccine composed primarily of F glycoprotein
Number of subjects: 26

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 26
Study: 3097693

Group type: EXPERIMENTAL
Intervention: L-tryptophan (3 g)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31318264

Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU)
Number of subjects: 321

Group type: COMPARATOR
Intervention: School-as-usual control group
Number of subjects: 321
Study: 30279397

Group type: EXPERIMENTAL
Intervention: DHA-rich fish oil supplement (EPAX: 1600 mg DHA + 400 mg EPA)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 38
Study: 28977255

Group type: EXPERIMENTAL
Intervention: Maximum stepwise alveolar recruitment associated with PEEP titration (ART strategy)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional treatment (ARDSNet strategy)
Number of subjects: 120
Study: 26638670

Group type: EXPERIMENTAL
Intervention: Sani Cloth CHG 2% wipes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control wipe
Number of subjects: 0